A successful response to requests for additional information would bring the Company one step closer to introducing this pioneering healthcare…
The first project under a new multi-year research collaboration, interrogation of the TAILORx breast cancer trial enables discovery for risk…
Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndromeBurgeoning pet care market also presents growth opportunities for…
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present…
Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for…
Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration…
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models…
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company…
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically…
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the…